🚀 VC round data is live in beta, check it out!
Pyridam Farma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Pyridam Farma and similar public comparables like Acepodia, MediWound, Egetis Therapeutics, Context Therapeutics and more.
Pyridam Farma Overview
About Pyridam Farma
PT Pyridam Farma Tbk is engaged in the production and development of pharmaceutical medicines and the trading of medical equipment. It manufactures products namely Antibiotics, Vitamins, Supplements, and Traditional herbal care. It operates through two segments namely Pharmaceutical Products and Toll Manufacturing Services; and Medical Device Products. The company derives maximum revenue from Pharmaceutical Products and Toll Manufacturing Services. The company's products include consumer health, Derma, prescription, and biomedilab.
Founded
1976
HQ
Employees
1.4K
Website
Financials (FY)
EV
$504M
Pyridam Farma Financials
Pyridam Farma reported last fiscal year revenue of $161M and negative EBITDA of ($7M).
In the same fiscal year, Pyridam Farma generated $34M in gross profit, ($7M) in EBITDA losses, and had net loss of ($22M).
Pyridam Farma P&L
In the most recent fiscal year, Pyridam Farma reported revenue of $161M and EBITDA of ($7M).
Pyridam Farma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $161M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $34M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 21% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($7M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (4%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (6%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($22M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (14%) | XXX | XXX | XXX |
| Net Debt | — | — | $206M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Pyridam Farma Stock Performance
Pyridam Farma has current market cap of $227M, and enterprise value of $504M.
Market Cap Evolution
Pyridam Farma's stock price is $0.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $504M | $227M | -0.4% | XXX | XXX | XXX | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPyridam Farma Valuation Multiples
Pyridam Farma trades at 3.1x EV/Revenue multiple, and (74.4x) EV/EBITDA.
Pyridam Farma Financial Valuation Multiples
As of April 18, 2026, Pyridam Farma has market cap of $227M and EV of $504M.
Equity research analysts estimate Pyridam Farma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pyridam Farma has a P/E ratio of (10.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $227M | XXX | $227M | XXX | XXX | XXX |
| EV (current) | $504M | XXX | $504M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 3.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (74.4x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (51.1x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 14.8x | XXX | XXX | XXX |
| P/E | — | XXX | (10.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (16.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Pyridam Farma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Pyridam Farma Margins & Growth Rates
Pyridam Farma's revenue in the last fiscal year grew by 44%.
Pyridam Farma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Pyridam Farma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 44% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (4%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 278% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 27% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Pyridam Farma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Pyridam Farma | XXX | XXX | XXX | XXX | XXX | XXX |
| Acepodia | XXX | XXX | XXX | XXX | XXX | XXX |
| MediWound | XXX | XXX | XXX | XXX | XXX | XXX |
| Egetis Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Context Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Keros Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pyridam Farma M&A Activity
Pyridam Farma acquired XXX companies to date.
Last acquisition by Pyridam Farma was on XXXXXXXX, XXXXX. Pyridam Farma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Pyridam Farma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPyridam Farma Investment Activity
Pyridam Farma invested in XXX companies to date.
Pyridam Farma made its latest investment on XXXXXXXX, XXXXX. Pyridam Farma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Pyridam Farma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Pyridam Farma
| When was Pyridam Farma founded? | Pyridam Farma was founded in 1976. |
| Where is Pyridam Farma headquartered? | Pyridam Farma is headquartered in Indonesia. |
| How many employees does Pyridam Farma have? | As of today, Pyridam Farma has over 1K employees. |
| Is Pyridam Farma publicly listed? | Yes, Pyridam Farma is a public company listed on Indonesia Stock Exchange. |
| What is the stock symbol of Pyridam Farma? | Pyridam Farma trades under PYFA ticker. |
| When did Pyridam Farma go public? | Pyridam Farma went public in 2001. |
| Who are competitors of Pyridam Farma? | Pyridam Farma main competitors are Acepodia, MediWound, Egetis Therapeutics, Context Therapeutics. |
| What is the current market cap of Pyridam Farma? | Pyridam Farma's current market cap is $227M. |
| What is the current revenue of Pyridam Farma? | Pyridam Farma's last fiscal year revenue is $161M. |
| What is the current EV/Revenue multiple of Pyridam Farma? | Current revenue multiple of Pyridam Farma is 3.1x. |
| Is Pyridam Farma profitable? | No, Pyridam Farma is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.